Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema

09:59 AM EDT, 09/08/2026 (MT Newswires) -- Intellia Therapeutics (NTLA) said Tuesday that the US Food and Drug Administration has accepted the biologics license application for lonvo-z for the treatment of hereditary angioedema. The FDA has also granted the BLA priority review and has set a Prescription Drug User Fee Act target date of March 10, 2027, according to a statement. The biopharmaceutical further said that the FDA has advised that it is currently not planning to hold an advisory committee to discuss the application. Shares of the company were down 1.6% in early Tuesday trading. Price: 12.49, Change: -0.26, Percent Change: -2.00